dc.contributor.author |
Jones, Paul
|
en_ZA |
dc.contributor.author |
Rennard, Stephen
|
en_ZA |
dc.contributor.author |
Agusti, Alvar
|
en_ZA |
dc.contributor.author |
Chanez, Pascal
|
en_ZA |
dc.contributor.author |
Magnussen, Helgo
|
en_ZA |
dc.contributor.author |
Fabbri, Leonardo
|
en_ZA |
dc.contributor.author |
Donohue, James
|
en_ZA |
dc.contributor.author |
Bateman, Eric
|
en_ZA |
dc.contributor.author |
Gross, Nicholas
|
en_ZA |
dc.contributor.author |
Lamarca, Rosa
|
en_ZA |
dc.contributor.author |
Caracta, Cynthia
|
en_ZA |
dc.contributor.author |
Gil, Esther
|
en_ZA |
dc.date.accessioned |
2015-11-11T11:53:41Z |
|
dc.date.available |
2015-11-11T11:53:41Z |
|
dc.date.issued |
2011 |
en_ZA |
dc.identifier.citation |
Jones, P. W., Rennard, S. I., Agusti, A., Chanez, P., Magnussen, H., Fabbri, L., ... & Gil, E. G. (2011). Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory research, 12(1), 55. |
en_ZA |
dc.identifier.uri |
http://hdl.handle.net/11427/14859
|
|
dc.identifier.uri |
http://dx.doi.org/10.1186/1465-9921-12-55
|
|
dc.description.abstract |
BACKGROUND: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). METHODS: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomised to inhaled aclidinium 200 mug or placebo once-daily. Patients were required to have a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of [less than or equal to]70% and FEV1 <80% of the predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status measured by St George's Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation. RESULTS: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement [greater than or equal to]4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies. CONCLUSION: Aclidinium is effective and well tolerated in patients with moderate to severe COPD.TRIAL REGISTRATION:ClinicalTrials.gov: NCT00363896 (ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II). |
en_ZA |
dc.language.iso |
eng |
en_ZA |
dc.publisher |
BioMed Central Ltd |
en_ZA |
dc.rights |
This is an Open Access article distributed under the terms of the Creative Commons Attribution License |
en_ZA |
dc.rights.uri |
http://creativecommons.org/licenses/by/2.0 |
en_ZA |
dc.source |
Respiratory Research |
en_ZA |
dc.source.uri |
http://www.respiratory-research.com/
|
en_ZA |
dc.subject.other |
Aclidinium bromide |
en_ZA |
dc.subject.other |
anticholinergic |
en_ZA |
dc.subject.other |
chronic obstructive pulmonary disease |
en_ZA |
dc.subject.other |
long-acting muscarinic antagonist |
en_ZA |
dc.title |
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease |
en_ZA |
dc.type |
Journal Article |
en_ZA |
dc.rights.holder |
2011 Jones et al; licensee BioMed Central Ltd. |
en_ZA |
uct.type.publication |
Research |
en_ZA |
uct.type.resource |
Article
|
en_ZA |
dc.publisher.institution |
University of Cape Town |
|
dc.publisher.faculty |
Faculty of Health Sciences |
en_ZA |
dc.publisher.department |
Division of Pulmonology |
en_ZA |
uct.type.filetype |
Text |
|
uct.type.filetype |
Image |
|
dc.identifier.apacitation |
Jones, P., Rennard, S., Agusti, A., Chanez, P., Magnussen, H., Fabbri, L., ... Gil, E. (2011). Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. <i>Respiratory Research</i>, http://hdl.handle.net/11427/14859 |
en_ZA |
dc.identifier.chicagocitation |
Jones, Paul, Stephen Rennard, Alvar Agusti, Pascal Chanez, Helgo Magnussen, Leonardo Fabbri, James Donohue, et al "Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease." <i>Respiratory Research</i> (2011) http://hdl.handle.net/11427/14859 |
en_ZA |
dc.identifier.vancouvercitation |
Jones P, Rennard S, Agusti A, Chanez P, Magnussen H, Fabbri L, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respiratory Research. 2011; http://hdl.handle.net/11427/14859. |
en_ZA |
dc.identifier.ris |
TY - Journal Article
AU - Jones, Paul
AU - Rennard, Stephen
AU - Agusti, Alvar
AU - Chanez, Pascal
AU - Magnussen, Helgo
AU - Fabbri, Leonardo
AU - Donohue, James
AU - Bateman, Eric
AU - Gross, Nicholas
AU - Lamarca, Rosa
AU - Caracta, Cynthia
AU - Gil, Esther
AB - BACKGROUND: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD). METHODS: In two double-blind, 52-week studies, ACCLAIM/COPD I (n = 843) and II (n = 804), patients were randomised to inhaled aclidinium 200 mug or placebo once-daily. Patients were required to have a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity ratio of [less than or equal to]70% and FEV1 <80% of the predicted value. The primary endpoint was trough FEV1 at 12 and 28 weeks. Secondary endpoints were health status measured by St George's Respiratory Questionnaire (SGRQ) and time to first moderate or severe COPD exacerbation. RESULTS: At 12 and 28 weeks, aclidinium improved trough FEV1 versus placebo in ACCLAIM/COPD I (by 61 and 67 mL; both p < 0.001) and ACCLAIM/COPD II (by 63 and 59 mL; both p < 0.001). More patients had a SGRQ improvement [greater than or equal to]4 units at 52 weeks with aclidinium versus placebo in ACCLAIM/COPD I (48.1% versus 39.5%; p = 0.025) and ACCLAIM/COPD II (39.0% versus 32.8%; p = 0.074). The time to first exacerbation was significantly delayed by aclidinium in ACCLAIM/COPD II (hazard ratio [HR] 0.7; 95% confidence interval [CI] 0.55 to 0.92; p = 0.01), but not ACCLAIM/COPD I (HR 1.0; 95% CI 0.72 to 1.33; p = 0.9). Adverse events were minor in both studies. CONCLUSION: Aclidinium is effective and well tolerated in patients with moderate to severe COPD.TRIAL REGISTRATION:ClinicalTrials.gov: NCT00363896 (ACCLAIM/COPD I) and NCT00358436 (ACCLAIM/COPD II).
DA - 2011
DB - OpenUCT
DO - 10.1186/1465-9921-12-55
DP - University of Cape Town
J1 - Respiratory Research
LK - https://open.uct.ac.za
PB - University of Cape Town
PY - 2011
T1 - Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
TI - Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
UR - http://hdl.handle.net/11427/14859
ER -
|
en_ZA |